Bone Biologics Corp - Form 8-K Summary
Business Context and Reporting Period
This is a Current Report on Form 8-K filed by Bone Biologics Corp, an emerging growth company incorporated in Delaware. The report covers events occurring on August 1, 2018, and was signed on August 6, 2018.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
Effective August 1, 2018, Jimmy Delshad resigned as a director of the Company. No other material financial or operational changes were disclosed in this filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the director resignation.
Key Facts for Investors to Verify
- Confirmation of Jimmy Delshad's resignation effective date (August 1, 2018).
- Whether a replacement director has been appointed or if the board is currently understaffed.
- Any potential impact of this resignation on the company's strategic direction or board oversight.